CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Chateau Gontier Cedex, France

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

    Phase

    2

    Span

    213 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Oaxaca

    Recruiting

  • A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

    Buloxibutid is an oral angiotensin II type 2 (AT2) receptor agonist and has been shown to improve lung function in IPF over 36 weeks. Buloxibutid agonizes the AT2 receptor on alveolar epithelial type 2 cells (AEC2s), which are believed to play a central role in the disease. Buloxibutid has been demonstrated preclinically to improve AEC2 viability, alveolar integrity via surfactant secretion and epithelial repair via replenishment of gas exchange alveolar epithelial type 1 cells (AEC1s). This leads to decreasing downstream profibrotic signaling, enhancing resolution of existing fibrotic tissue via upregulation of collagenase matrix metalloproteinases, and addressing vascular disfunction associated with the disease. The trial will include participants who are on stable licensed IPF therapy or who are currently not treated with a licensed IPF therapy. The latter group will include participants intolerant or not responsive to licensed IPF therapies, participants ineligible to receive these therapies, and participants who have voluntarily declined to receive a licensed IPF therapy after being fully informed of the potential benefits and risks of such therapy. Due to the potential risk of drug-drug interactions (DDIs), concomitant treatment with pirfenidone is not allowed in this trial. Participants who are not on antifibrotic therapy at study start may initiate such treatment during the study. The trial is planned to enroll 270 participants, 90 participants on oral buloxibutid 100 mg BID, 90 participants on oral buloxibutid 50 mg BID, and 90 participants on oral placebo BID for 52 weeks. The treatment will be blinded and treatment allocation will be randomized. The primary measurement will be based on spirometry, measuring the forced vital capacity (FVC). The trial consists of 3 consecutive periods: a screening period of up to 6 weeks, a 52-week treatment period, and a follow-up period of 2-4 weeks after the 52-week visit. The study procedures have been planned with focus on optimizing patient convenience while allowing a safe conduct and strict scientific rigor. Trial website: www.aspire-ipf.com

    Phase

    2

    Span

    121 weeks

    Sponsor

    Vicore Pharma AB

    Oaxaca

    Recruiting

  • An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

    Phase

    3

    Span

    113 weeks

    Sponsor

    GlaxoSmithKline

    Oaxaca

    Recruiting

    Healthy Volunteers

  • A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

    Acquired from Horizon in 2024.

    Phase

    3

    Span

    132 weeks

    Sponsor

    Amgen

    Oaxaca

    Recruiting

  • Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    Phase

    3

    Span

    387 weeks

    Sponsor

    GlaxoSmithKline

    Oaxaca

    Recruiting

  • A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

    Phase

    3

    Span

    258 weeks

    Sponsor

    Bristol-Myers Squibb

    Oaxaca

    Recruiting

  • Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

    The primary objectives of the study are Progression Free Survival (PFS) and Overall Survival (OS) as first line therapy in participants with programmed death-ligand 1 (PD-L1) TPS <50% and advanced or metastatic NSCLC without actionable genomic alternations. Eligible participants will be randomized in a 1:1:1 ratio to a) Dato-DXd plus pembrolizumab plus platinum; b) Dato-DXd plus pembrolizumab; or c) pembrolizumab plus pemetrexed plus platinum. Platinum therapy will be either carboplatin or cisplatin at investigator discretion. The study will be divided into three periods: Screening Period (including tissue screening), Treatment Period, and Follow-up Period.

    Phase

    3

    Span

    238 weeks

    Sponsor

    Daiichi Sankyo

    Oaxaca

    Recruiting

  • Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    Phase

    1

    Span

    374 weeks

    Sponsor

    Pfizer

    Oaxaca

    Recruiting

  • Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

    This trial will evaluate the efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or ianalumab given every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN (ISN/RPS class III, IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous). using the 2003 International Society for Nephrology (ISN)/Renal Pathology Society (RPS) criteria).

    Phase

    3

    Span

    418 weeks

    Sponsor

    Novartis Pharmaceuticals

    Oaxaca

    Recruiting

  • A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

    Phase

    3

    Span

    445 weeks

    Sponsor

    AstraZeneca

    Oaxaca

    Recruiting

1-10 of 46
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information